Olema Pharmaceuticals press release ( OLMA ): Q1 GAAP EPS of -$0.52 beats by $0.01 . Cash, cash equivalents, and marketable securities as of March 31, 2026, were $505.3 million. More on Olema Pharmaceuticals Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: ...
Olema Pharmaceuticals press release ( OLMA ): Q1 GAAP EPS of -$0.52 beats by $0.01 . Cash, cash equivalents, and marketable securities as of March 31, 2026, were $505.3 million. More on Olema Pharmaceuticals Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript Seeking Alpha’s Quant Rating on Olema Pharmaceuticals Historical earnings data for Olema Pharmaceuticals Financial information for Olema Pharmaceuticals
hernan4429/iStock via Getty Images Some REITs are much riskier than investors realize. Investors often buy REITs, thinking that this is income-producing real estate. How could the management mess it up, especially in the case of a large and well-diversified portfolio? Well... Unfortunately, this happens far more often than you would imagine, and in today's article, I am going to highlight 3 REITs ...
hernan4429/iStock via Getty Images Some REITs are much riskier than investors realize. Investors often buy REITs, thinking that this is income-producing real estate. How could the management mess it up, especially in the case of a large and well-diversified portfolio? Well... Unfortunately, this happens far more often than you would imagine, and in today's article, I am going to highlight 3 REITs facing significant risks. All three have these things in common: They are externally managed, which can lead to greater conflicts of interest. They have more leverage than your average REIT, likely at least in part because their management is getting paid based on the volume of assets under management. They have poor long-term track records, underperforming REIT sector benchmarks ( VNQ ). They own troubled assets. Yet, they are popular because they trade at relatively low valuations and high dividend yields. Let's start with a popular mortgage REIT: KKR Real Estate Finance ( KREF ) Earlier this year, I predicted that KKR Real Estate Finance would likely cut its dividend, even as the management was telling investors that they were comfortable with their current dividend. That cut just came, reducing the dividend by 60%. The management tried to reassure the market that this dividend cut was not the result of liquidity constraints but rather their desire to reinvest in growth and buybacks. But this is the reaction of the market: Data by YCharts And this drop is just the latest dip in a decade-long slide: Data by YCharts It is hard to have faith in a REIT when they have managed to lose 70% of their value since their IPO nearly a decade ago. If you listen to their earnings call, it always seems positive, but the fundamentals paint a different picture. The mortgage REIT is in trouble today because it simply has too much leverage, and it holds exposure to many troubled assets. Its leverage is one of the highest of any mortgage REIT, with about a 4x debt-to-equity ratio, which leav...
Andrzej Rostek/iStock via Getty Images Introduction Price is what you pay, value is what you get . Most investors are familiar with this famous quote from Warren Buffett, highlighting the importance of knowing the difference between a stock's share price and its intrinsic value. In my opinion, this is probably the hardest thing about investing. Finding and buying quality businesses is the easy par...
Andrzej Rostek/iStock via Getty Images Introduction Price is what you pay, value is what you get . Most investors are familiar with this famous quote from Warren Buffett, highlighting the importance of knowing the difference between a stock's share price and its intrinsic value. In my opinion, this is probably the hardest thing about investing. Finding and buying quality businesses is the easy part. The difficult part is finding them at attractive valuations. With the growing popularity of ETFs, the space is becoming crowded. And it's becoming more difficult for funds to differentiate themselves. But the ETF I discuss today is relatively new and has growth characteristics worth watching closely. It's also attractive for investors looking to rotate from mega-cap growth into value plays. In this article, I discuss its performance so far and why investors should put this fund on their watchlist. W ho Is CGVV? Capital Group U.S. Large Value ETF ( CGVV ) is another fund from the Capital Group family. CGVV has an inception date of June 24, 2025, so a little less than a year public. Investors may be familiar with their sister fund, Capital Group's Dividend Value ETF ( CGDV ), which has grown quite popular with investors here on Seeking Alpha. In fact, CGDV has become a core position in my portfolio. I published an article on them last month that you can read here . For me, I usually look for funds with at least a year's worth of data to analyze. But this is also not a hard stop for me to consider them as an investment. But some investors may consider these too early to tell since they have limited data and are usually significantly smaller in size. Currently, CGVV has $131.3 million in assets under management. Like other funds in the family, CGVV has an expense ratio of 0.33% and also uses multiple portfolio managers. CGVV uses three portfolio managers, while their sister fund, CGDV, uses five. Two of CGVV's managers also manage CGDV. So, I believe that's a plus since CGDV...
Delivery Hero ( DLVHF ) Tuesday said that Niklas Östberg, co-founder and CEO, will hand over leadership of the company by March 31, 2027. Östberg will remain CEO during the transition, leading the next phase of the strategic review and associated M&A processes, which were initiated jointly by the management and supervisory boards and announced in December 2025. The supervisory board will launch th...
Delivery Hero ( DLVHF ) Tuesday said that Niklas Östberg, co-founder and CEO, will hand over leadership of the company by March 31, 2027. Östberg will remain CEO during the transition, leading the next phase of the strategic review and associated M&A processes, which were initiated jointly by the management and supervisory boards and announced in December 2025. The supervisory board will launch the search for a new CEO shortly with an aim to conclude this process by year-end 2026. More on Delivery Hero SE Delivery Hero SE (DELHY) Q1 2026 Sales/Trading Call Transcript Delivery Hero Still Does Not Have A Clear Path To Sustained Profitability Delivery Hero SE (DELHY) Grab Holdings Limited - M&A Call - Slideshow Delivery Hero jumps after Prosus stake sale to Aspex Management Historical earnings data for Delivery Hero SE
Camtek press release ( CAMT ): Q1 Non-GAAP EPS of $0.70 beats by $0.02 . Revenue of $121.7M (+2.6% Y/Y) beats by $1.55M . Cash and cash equivalents, short-term and long-term deposits, and marketable securities, as of March 31, 2026, were $849.7 million compared to $851.1 million as of December 31, 2025, and $522.6 million as of March 31, 2025. During the first quarter, the Company generated an ope...
Camtek press release ( CAMT ): Q1 Non-GAAP EPS of $0.70 beats by $0.02 . Revenue of $121.7M (+2.6% Y/Y) beats by $1.55M . Cash and cash equivalents, short-term and long-term deposits, and marketable securities, as of March 31, 2026, were $849.7 million compared to $851.1 million as of December 31, 2025, and $522.6 million as of March 31, 2025. During the first quarter, the Company generated an operating cash flow of $3.1 million. Forward-Looking Expectations Based on Camtek's backlog and pipeline, guidance for the second quarter is for revenues between $129 million and $131 million vs. $126.26M consensus . Expects a significant increase in second half 2026 with revenues expected to grow by over 25% versus first half 2026 revenues. More on Camtek Camtek: Why I'm Calling A Buy At Current Levels Camtek: An Enticing HBM Opportunity, But Better Off On The Watchlist For Now Camtek: Riding The AI Wave, But I'll Pass Camtek Q1 2026 Earnings Preview Camtek to acquire Visual Layer to expand AI inspection capabilities
(RTTNews) - Yum China Holdings, Inc. (YUMC), on Tuesday announced share repurchase agreements in the U.S. and Hong Kong for an aggregate repurchase amount of approximately $512 million for the second half of 2026, beginning July 1.
(RTTNews) - Yum China Holdings, Inc. (YUMC), on Tuesday announced share repurchase agreements in the U.S. and Hong Kong for an aggregate repurchase amount of approximately $512 million for the second half of 2026, beginning July 1.
adventtr/iStock via Getty Images Thesis While Qualcomm's ( QCOM ) Handsets legacy business subsegment is facing short-term headwinds from DRAM shortages and Apple's exit, Handsets is expected to be a strong revenue source in the long-term, thanks to a growing market size, a higher mix of premium-tier handsets and an incoming device upgrade cycle driven by agentic AI. At the same time, Automotive a...
adventtr/iStock via Getty Images Thesis While Qualcomm's ( QCOM ) Handsets legacy business subsegment is facing short-term headwinds from DRAM shortages and Apple's exit, Handsets is expected to be a strong revenue source in the long-term, thanks to a growing market size, a higher mix of premium-tier handsets and an incoming device upgrade cycle driven by agentic AI. At the same time, Automotive and IoT subsegments are showing exceptional execution, beating past projected targets and making impactful technology upgrades that allow it to enter more and more new initiatives on these markets. As all these new initiatives keep translating into significant deals and partnerships, Qualcomm revenue will keep getting more diversified and its TAM will keep expanding, making the market reassess its value proposition through a PE multiple expansion. Company Analysis Qualcomm has 3 reportable segments: QCL, QTL and QSI. However, QSI revenue is negligible, so in practice revenue is derived from QCT and QTL, with QSI being more about investment on innovative optionality, primarily through non-marketable equity securities. Specifically, these segments accounted for 87.3% (QCT), 12.7% (QTL) and 0% ( QSI ) of FY25 revenue, and 73.4% (QCT), 25.4% (QCT) and 1.1% of EBT ( Earnings before Taxes ). QCT (Qualcomm CDMA Technologies ) offering is composed of integrated circuits and systems software that it sells to the Industrial, Consumer Electronics and Automotive industries. Its reportable subsegments are: Handsets (mostly smartphones), IoT (includes industrial networking, robotics, PCs, XR devices, and other smart wearables) and Automotive, which includes emerging features like Advanced Driving Assistance Systems (ADAS) and Automated Driving ( AD ). The EBT for this segment was 30% of revenue in FY25 and 29% in FY24, according to the 2025 10-K. QCOM Product Categories (Investor Day 2024 Slide Deck) QCOM integrated circuits consist of a System-on-Chip (SoC) setting, which is composed of ...
Arvinas press release ( ARVN ): Q1 GAAP EPS of -$0.90 misses by $0.26 . Revenue of $15.6M (-91.7% Y/Y) misses by $19.24M . More on Arvinas Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript Arvinas Q1 2026 Earnings Preview Pfizer, Arvinas breast cancer therapy approved by the FDA Seeking Alpha’s Quant ...
Arvinas press release ( ARVN ): Q1 GAAP EPS of -$0.90 misses by $0.26 . Revenue of $15.6M (-91.7% Y/Y) misses by $19.24M . More on Arvinas Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript Arvinas Q1 2026 Earnings Preview Pfizer, Arvinas breast cancer therapy approved by the FDA Seeking Alpha’s Quant Rating on Arvinas
Mitsubishi Heavy Industries press release ( MHVYF ): FY order intake rose to 7,653.6B yen, up 1,248.4B yen year-over-year Revenue increased to 4,974.1B yen, up 613.0B yen year-over-year Profit from business activities climbed to 432.2B yen, up 77.2B yen year-over-year Profit attributable to owners of parent grew to 332.1B yen, up 86.6B yen year-over-year FY2026 order intake forecast at 6,800.0B ye...
Mitsubishi Heavy Industries press release ( MHVYF ): FY order intake rose to 7,653.6B yen, up 1,248.4B yen year-over-year Revenue increased to 4,974.1B yen, up 613.0B yen year-over-year Profit from business activities climbed to 432.2B yen, up 77.2B yen year-over-year Profit attributable to owners of parent grew to 332.1B yen, up 86.6B yen year-over-year FY2026 order intake forecast at 6,800.0B yen FY2026 revenue forecast at 5,400.0B yen FY2026 profit from business activities forecast at 540.0B yen FY2026 profit attributable to owners of parent forecast at 380.0B yen More on Mitsubishi Heavy Industries, Ltd. Australia, Japan Seal $6.5B warship deal; Mitsubishi Heavy shares rise on 3 Mogami frigates order Alaska takes step closer to first new U.S. coal power plant since 2013 Historical earnings data for Mitsubishi Heavy Industries, Ltd. Financial information for Mitsubishi Heavy Industries, Ltd.
eToro Group Ltd. press release ( ETOR ): Q1 Non-GAAP EPS of $0.91 beats by $0.21 . Revenue of $2.44B (-35.1% Y/Y). Net contribution increased by 19% year-over-year to $258 million, compared to $217 million in the first quarter of 2025, driven primarily by increased commodities trading activity. Adjusted EBITDA (Non-GAAP) increased by 35% year-over-year to $109 million, compared to $80 million in t...
eToro Group Ltd. press release ( ETOR ): Q1 Non-GAAP EPS of $0.91 beats by $0.21 . Revenue of $2.44B (-35.1% Y/Y). Net contribution increased by 19% year-over-year to $258 million, compared to $217 million in the first quarter of 2025, driven primarily by increased commodities trading activity. Adjusted EBITDA (Non-GAAP) increased by 35% year-over-year to $109 million, compared to $80 million in the first quarter of 2025, largely due to increased net contribution. Funded Accounts increased 12% year-over-year to 4.02 million compared to 3.58 million in the first quarter of 2025. Assets under Administration grew by 15% year-over-year to $17.0 billion, compared to $14.8 billion in the first quarter of 2025. Cash, Cash Equivalents and Short Term Investments were $1.3 billion as of March 31, 2026. eToro also reported the below selected monthly business metrics for April 2026: Assets under Administration were $18.7 billion, up 19% year-over-year. Funded Accounts were 4.07 million, up 13% year-over-year. Capital Markets/ECC Activity Total number of trades for April was 63 million, up 50% year-over-year; Invested amount per trade for April was $197, down 48% year-over-year. Crypto Activity Total number of trades for April was 2 million, down 32% year-over-year; Invested amount per trade for April was $207, down 22% year-over-year. Interest Earning Assets for April were $7.0 billion, up 28% year-over-year. Total Money Transfers for April were $1.4 billion, up 53% year-over-year. More on eToro Group Ltd. eToro Q1 Preview: Interesting Moat On Its Hands, But Execution Risks Remain eToro: The Deep Value Play, And Why I Am Still Waiting To Buy It eToro: The Rebound Is Just Beginning As Net Inflows Rise eToro Group Ltd. Q1 2026 Earnings Preview Robinhood, Webull, eToro shares jump after SEC removes day-trading limit
Immatics press release ( IMTX ): Q1 GAAP EPS of - € 0.43. Revenue of € 7.61M (-59.0% Y/Y). More on Immatics Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot Seeking Alpha’s Quant Rating on Immatics Historical earnings data for Immatics Financial information for Immatics
Immatics press release ( IMTX ): Q1 GAAP EPS of - € 0.43. Revenue of € 7.61M (-59.0% Y/Y). More on Immatics Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot Seeking Alpha’s Quant Rating on Immatics Historical earnings data for Immatics Financial information for Immatics
C4 Therapeutics press release ( CCCC ): Q1 GAAP EPS of -$0.20 beats by $0.06 . Revenue of $6.15M (-15.1% Y/Y) beats by $1.73M . Cash, cash equivalents and marketable securities as of March 31, 2026 were $268.3 million, compared to $297.1 million as of December 31, 2025. The decrease in cash, cash equivalents and marketable securities during the first quarter of 2026 was primarily the result of the...
C4 Therapeutics press release ( CCCC ): Q1 GAAP EPS of -$0.20 beats by $0.06 . Revenue of $6.15M (-15.1% Y/Y) beats by $1.73M . Cash, cash equivalents and marketable securities as of March 31, 2026 were $268.3 million, compared to $297.1 million as of December 31, 2025. The decrease in cash, cash equivalents and marketable securities during the first quarter of 2026 was primarily the result of the cash used to fund operations and advance our programs. The company expects that its current cash, cash equivalents and marketable securities will fund its operations to the end of 2028. More on C4 Therapeutics C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact C4 Therapeutics, Inc. (CCCC) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates Seeking Alpha’s Quant Rating on C4 Therapeutics
Tenax Therapeutics press release ( TENX ): Q1 GAAP EPS of -$0.35 beats by $0.05 . Tenax Therapeutics reported cash and cash equivalents of $118.8 million as of March 31, 2026. The proceeds from exercises of previously issued warrants during the quarter have enabled Tenax to extend its cash runway, and the Company now expects cash and cash equivalents to fund it through at least the first quarter o...
Tenax Therapeutics press release ( TENX ): Q1 GAAP EPS of -$0.35 beats by $0.05 . Tenax Therapeutics reported cash and cash equivalents of $118.8 million as of March 31, 2026. The proceeds from exercises of previously issued warrants during the quarter have enabled Tenax to extend its cash runway, and the Company now expects cash and cash equivalents to fund it through at least the first quarter of 2028. More on Tenax Therapeutics Tenax Therapeutics: A Binary Bet With Heavy Downside Likely Tenax Therapeutics: Some Future Potential Tenax Therapeutics appoints Thomas Staab as chief financial officer Tenax wins bullish view at Cantor ahead of pivotal readout Seeking Alpha’s Quant Rating on Tenax Therapeutics